John M. Timmerman
Associate Professor of Medicine · UCLA Health
Credentials: · ·
History
- Present
UCLA Health
Until 1998- Until 1994
UC San Francisco School of Medicine
- Until 1992
UC San Francisco School of Medicine
Research
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
New England Journal of Medicine · 2015 · 2,937 citations
The Lancet Oncology · 2019 · 1,921 citations
21 papers
12 papers
12 papers
11 papers
- DB
10 papers
8 papers
8 papers
- JM
8 papers
Grants
- 2002–2018
Academic Training in Hematology
National Heart, Lung, and Blood Institute · T32
Contact PI · $1.1M · University of California Los Angeles
- 2010–2016
Antibody-CpG Conjugates for the Treatment of B Cell Lymphoma
National Cancer Institute · R01
Contact PI · $1.5M · University of California Los Angeles
- 2005–2008
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $9.5K · University of California Los Angeles
- 2004–2007
Anti-CTLA-4 Monoclonal Antibody Therapy for Lymphoma
National Cancer Institute · R21
Contact PI · $505.3K · University of California Los Angeles
Clinical trials
- 2021–2025
A Study of IGN002 for Refractory NHL
Principal investigator · Withdrawn · Phase 1
Spectrum Pharmaceuticals, Inc
- 2020–2026
Principal investigator · Terminated · Phase 2
Jonsson Comprehensive Cancer Center
- 2025–2031
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Sub-investigator · Recruiting · Phase 1, Phase 2
Jonsson Comprehensive Cancer Center